Bristol-Myers Squibb (BMY) just handed investors a compelling new reason to pay attention to BMY stock, and it could matter more than the market is giving it credit for. The pharmaceutical giant's new artificial intelligence (AI) partnership with Anthropic could be a key catalyst, not just a headline — and when you layer it on top of the company's already strong pipeline momentum, the case for owning this blue-chip stock into 2030 gets a lot more interesting.
Let's take a closer look.